Список литературы

1) Sheth S., Bedford A., Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. American Journal of Gastroenterology. 2000. - N 95. - С. 1402 - 1410.

2) Hueman M.T., Vollmer C.M., Pawlik T.M. Evolving treatment strategies for gallbladder cancer. Annals of Surgical Oncology. - 2009. - N 16. - С. 2101 - 2115.

3) Hundal R., Shaffer E.A. Gallbladder cancer: epidemiology and outcome. Clinical Epidemiology. - 2014. - N 6. - С. 99 - 109.

4) Patel T. Cholangiocarcinoma - controversies and challenges. Nature Reviews Gastroenterology Hepatology. 2011. - N 8. - С. 189 - 200.

5) Yamamoto S., Kubo S., Hai S., et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Science. 2004. - N 95. - С. 592 - 595.

6) Welzel T.M., Graubard B.I., El-Serag H.B., et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clinical Gastroenterology Hepatology. 2007. - N 5. - С. 1221 - 1228.

7) Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность) - М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИРЦ" Минздрава России, - 2018. - илл. - 250 с.

8) Zhu A.X., Hong T.S., Hezel A.F., Kooby D.A. Current management of gallbladder carcinoma. Oncologist. 2010. - N 15. - С. 168 - 181.

9) Valle1 J.W., Borbath I., Khan S.A., et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Annals of Oncology 27 (Supplement 5): v28 - v37, 2016 doi: 10.1093/annonc/mdw324.

10) DeOliveira M.L., Cunningham S.C., Cameron J.L., et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Annals of Surgery. 2007. - N 245. - С. 755 - 762.

11) Lim J.H. Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. American Journal of Roentgenology. 2003. - N 181. - С. 819 - 827.

12) Hawkins W.G., DeMatteo R.P., Jarnagin W.R., et al. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Annals of Surgical Oncology. 2004. - N 11. - С. 310 - 315.

13) Jarnagin W.R., Ruo L., Little S.A., et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003. - N 98. - С. 1689 - 1700.

14) Furlan A., Ferris J.V., Hosseinzadeh K., Borhani A.A. Gallbladder carcinoma update: multimodality imaging evaluation, staging, and treatment options. American Journal of Roentgenology. - 2008. - N 191. - С. 1440 - 1447.

15) Miller G., Schwartz L.H., D"Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surgical Oncology Clinics of North America. 2007. - N 16. - С. 343 - 368.

16) Levy A.D., Murakata L.A., Rohrmann C.A., Jr. Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics. 2001. - N 21. - С. 295 - 314.

17) Petrowsky H., Wildbrett P., Husarik D.B., et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. Journal of Hepatology. 2006. - N 45(1). - С. 43 - 50.

18) Khan Z.S., Livingston E.H., Huerta S. Reassessing the need for prophylactic surgery in patients with porcelain gallbladder: case series and systematic review of the literature. Archives of Surgery. 2011. - N 146. - С. 1143 - 1147.

19) Eckel F., Brunner T. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Jelic Annals of Oncology 22 (Supplement 6): vi40 - vi44, 2011 clinical practice guidelines. doi:10.1093/annonc/mdr375

20) Zografos G., Farfaras A., Zagouri F., et al. Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreatic Diseases International. 2011. - 10(1). - С. 10 - 20.

21) Nagino M., Kamiya J., Nishio H., et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Annals of Surgery. 2006. - N 243. - С. 364 - 372.

22) Regimbeau J.M., Fuks D., Le Treut Y-P., et al. Surgery for Hilar Cholangiocarcinoma: A Multi-institutional Update on Practice and Outcome by the AFC-HC Study Group. Journal of Gastrointestinal Surgery. 2011. - N 15. - С. 480 - 488.

23) Coburn N.G., Cleary S.P., Tan J.C., Law C.H. Surgery for gallbladder cancer: a population-based analysis. Journal of the American College of Surgeons. 2008. - N 207. - С. 371 - 382.

24) Downing Sr CKOG, et al. Early-stage gallbladder cancer in the surveillance, epidemiology, and end results database: Effect of extended surgical resection. Archives of Surgery. 2011. - N 146. - С. 734 - 738.

25) Goetze T.O., Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma: analysis of the German registry. Annals of Surgery. 2008. - N 247. - С. 104 - 108.

26) Murakami Y., Uemura K., Sudo T., et al. Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma. Annals of Surgical Oncology. 2011. - N 18. - С. 651 - 658

27) Meyer C.G., Penn I., James L. Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation. - 2000. - N 69. - С. 1633 - 1637.

28) Zografos G., Farfaras A., Zagouri F., et al. Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreatic Diseases International. 2011. - N 10(1). - С. 10 - 20.

29) Neuhaus P., Jonas S., Settmacher U., et al. Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality. Langenbeck's Archives of Surgery. 2003. - N 388. - С. 194 - 200.

30) Nagino M., Kamiya J., Arai T., et al. "Anatomic" right hepatic trisectionectomy (extended right hepatectomy) with caudate lobectomy for hilar cholangiocarcinoma. Annals of Surgery. 2006. - N 243. - С. 28 - 32.

31) Бредер В.В., Косырев В.Ю., Ледин Е.В. Практические рекомендации по лекарственному лечению билиарного рака. RUSSCO. Версия 2017.

32) NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. - С. 140. - version 1.2018

33) Ma N (https://www.ncbi.nlm.nih.gov/pubmed/?term=Ma%20N%5BAuthor%5D&cauthor=true&cauthor_uid=26337466)., Cheng H (https://www.ncbi.nlm.nih.gov/pubmed/?term=Cheng%20H%5BAuthor%5D&cauthor=true&cauthor_uid=26337466)., Qin B (https://www.ncbi.nlm.nih.gov/pubmed/?term=Qin%20B%5BAuthor%5D&cauthor=true&cauthor_uid=26337466)., et al. Adjuvant therapy in the treatment of gallbladder cancer: a metaanalysis.BMC Cancer. (https://www.ncbi.nlm.nih.gov/pubmed/26337466) - 2015. - N 15. 615.

34) Ben-Josef E (https://www.ncbi.nlm.nih.gov/pubmed/?term=BenJosef%20E%5BAuthor%5D&cauthor=true&cauthor_uid=25964250)., Guthrie K.A (https://www.ncbi.nlm.nih.gov/pubmed/?term=Guthrie%20KA%5BAuthor%5D&cauthor=true&cauthor_uid=25964250)., El-Khoueiry A.B (https://www.ncbi.nlm.nih.gov/pubmed/?term=ElKhoueiry%20AB%5BAuthor%5D&cauthor=true&cauthor_uid=25964250)., et al. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. - Journal of Clinical Oncology. (https://www.ncbi.nlm.nih.gov/pubmed/25964250) - 2015. - N 33(24). - С. 2617 - 2622.

35) Fisher S.B., Patel S.H., Kooby D.A., et al. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB (Oxford). 2012. - N 14. - С. 514 - 522.

36) Hyder O., Hatzaras I., Sotiropoulos G.C., et al. Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery. 2013. - N 153. - С. 811 - 818.

37) Murakami Y., Uemura K., Sudo T., et al. Prognostic Factors After Surgical Resection for Intrahepatic, Hilar, and Distal Cholangiocarcinoma. Annals of Surgical Oncology. 2011. - N 18. - С. 651 - 658

38) Kelley S.T., Bloomston M., Serafini F., et al. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. The American Surgeon. 2004. - N 70. - С. 743 - 749.

39) Cereda S., Belli C., Reni M. Adjuvant treatment in biliary tract cancer: to treat or not to treat? World Journal of Gastroenterology. 2012. - N 18. - С. 2591 - 2596.

40) Mambrini A., Guglielmi A., Pacetti P., et al. Capecitabine plushepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study. Anticancer Research. 2007. - N 27. - С. 3009 - 3013.

41) Shitara K., Ikami I., Munakata M., et al. Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma. Clinical Oncology (R CollRadiol). 2008. - N 20. - С. 241 - 246.

42) Inaba Y., Arai Y., Yamaura H., et al. Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). American Journal of Clinical Oncology. 2011. - N 34. - С. 58 - 62.

43) Kemeny N.E., Schwartz L., Gonen M., et al. Treating primary live rcancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology. 2011. - N 80. - С. 153 - 159.

44) Boehm L.M., Jayakrishnan T.T., Miura J.T., et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. Journal of Surgical Oncology. 2015. - N 111. - С. 213 - 220.

45) Ortner M.E., Caca K., Berr F., et al. Successful photodynamic therapy for nonresectablecholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003. - N 125. - С. 1355 - 1363.

46) Zoepf T., Jakobs R., Arnold J.C., et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. American Journal of Gastroenterology. 2005. - N 100. - С. 2426 - 2430.

47) Ghafoori A.P., Nelson J.W., Willett C.G., et al. Radiotherapy in the Treatment of Patients with Unresectable Extrahepatic Cholangiocarcinoma. International Journal of Radiation Oncology, Biology, Physics. 2011. - N 81(3). - С. 654 - 659.

48) Eckel F., Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. British Journal of Cancer. 2007. - N 96. - С. 896 - 902.

49) Yonemoto N., Furuse J., Okusaka T., et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Japanese Journal of Clinical Oncology. 2007. - N 37. - С. 843 - 851.

50) Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New England Journal of Medicine. 2010. - N 362. - С. 1273 - 1281.